Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Rapporto sulle azioni

Cap. di mercato: US$7.9b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Intra-Cellular Therapies Gestione

Gestione criteri di controllo 3/4

Intra-Cellular Therapies' Il CEO è Sharon Mates, nominato in May2002, e ha un mandato di 22.25 anni. la retribuzione annua totale è $ 10.09M, composta da 8.8% di stipendio e 91.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.01% delle azioni della società, per un valore di $ 82.40M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.9 anni e 10.6 anni.

Informazioni chiave

Sharon Mates

Amministratore delegato

US$10.1m

Compenso totale

Percentuale dello stipendio del CEO8.8%
Mandato del CEO22.3yrs
Proprietà del CEO1.0%
Durata media del management5.9yrs
Durata media del Consiglio di amministrazione10.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Dec 24
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sharon Mates rispetto agli utili di Intra-Cellular Therapies?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$10mUS$892k

-US$140m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$228m

Dec 31 2022US$9mUS$849k

-US$256m

Sep 30 2022n/an/a

-US$298m

Jun 30 2022n/an/a

-US$321m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$7mUS$794k

-US$284m

Sep 30 2021n/an/a

-US$259m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$232m

Dec 31 2020US$5mUS$767k

-US$227m

Sep 30 2020n/an/a

-US$207m

Jun 30 2020n/an/a

-US$187m

Mar 31 2020n/an/a

-US$160m

Dec 31 2019US$5mUS$745k

-US$148m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$154m

Dec 31 2018US$4mUS$723k

-US$155m

Sep 30 2018n/an/a

-US$145m

Jun 30 2018n/an/a

-US$126m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$5mUS$702k

-US$98m

Compensazione vs Mercato: La retribuzione totale di Sharon ($USD 10.09M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.38M ).

Compensazione vs guadagni: La retribuzione di Sharon è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Sharon Mates (71 yo)

22.3yrs

Mandato

US$10,086,413

Compensazione

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Sharon Mates
Co-Founder22.3yrsUS$10.09m1.01%
$ 79.7m
Michael Halstead
Presidentless than a yearUS$3.53m0%
$ 0
Suresh Durgam
Executive VP & Chief Medical Officer6yrsUS$3.51m0.019%
$ 1.5m
Mark Neumann
EVP & Chief Commercial Officer5.8yrsUS$3.54m0.028%
$ 2.2m
Robert Davis
Senior VP & Chief Scientific Officer8.8yrsUS$2.13mNessun dato
Juan Sanchez
Vice President of Corporate Communications & Investor Relations10.4yrsUS$1.38mNessun dato
Karen Sheehy
Senior VP & Chief Compliance Officer5.1yrsNessun datoNessun dato
John Condon
Senior Vice Presidentno dataNessun datoNessun dato
Michael Olchaskey
Senior VP & Head of Regulatory Affairs5.9yrsNessun datoNessun dato
John Bardi
Senior VP of Market Access5.4yrsNessun datoNessun dato
Willie Earley
Senior VP & Head of Clinical Development2.3yrsNessun datoNessun dato

5.9yrs

Durata media

61yo

Età media

Gestione esperta: Il team dirigenziale di ITCI è esperto e expertise (durata media dell'incarico 5.9 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Sharon Mates
Co-Founder11yrsUS$10.09m1.01%
$ 79.7m
Rory Riggs
Independent Director10.6yrsUS$470.51k0.11%
$ 8.7m
Robert Van Nostrand
Lead Independent Director10.6yrsUS$507.58k0.011%
$ 844.5k
Joel Marcus
Independent Director11yrsUS$473.34k0.039%
$ 3.1m
Carol Tamminga
Chairman of Medical Advisory Boardno dataNessun datoNessun dato
John Kane
Member of Medical Advisory Boardno dataNessun datoNessun dato
Jeffrey Lieberman
Member of Medical Advisory Boardno dataNessun datoNessun dato
Christoph Correll
Member of Medical Advisory Boardno dataNessun datoNessun dato
Donald Goff
Member of Medical Advisory Boardno dataNessun datoNessun dato
Eduardo Salas
Independent Director2.3yrsUS$461.30k0.0015%
$ 116.5k

10.6yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ITCI è composto da personale esperto e esperto (durata media dell'incarico 10.6 anni).